Teva Pharmaceutical Industries

Teva, Axsome

Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.

Business Insider · 1d

Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva

Zacks.com on MSN · 1d

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva

Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the psychiatry drug,

Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Holdings Decreased by abrdn plc

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

13don MSN

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

10d

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Lowered to $26.00 at Barclays

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

12d

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Hosted on MSN12d

TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

STAT2h

Pharmalittle: We’re reading about pharma silence on Trump moves, lawmakers eyeing PBMs again, and more

A U.S. judge ordered federal agencies to restore access to health-related webpages and datasets removed by the Trump ...

13d

Why Teva Pharmaceutical Stock Is Sinking Today

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ...

Teva files automatic mixed securities shelf

EST Teva (TEVA) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results